Fourth, administration of neutralizing anti-PD-L1 antibody in mice with active EAE abolishes the protective effects of therapeutic OM-MOG, while mice with CD11c+ cell-specific deletion of PD-L1 remain fully protected, demonstrating a critical role for PD-L1 production by non-DC, possibly Ly6Chi and Ly6Clo myeloid cells and/or SSM, in OM-MOG immune tolerance. The gene discussed is ITGAX; the disease is ocular melanoma.